Payment overview · 2025
General Payments
$281.71
15 reported records · 10 companies
Healthcare provider profile · identity verified
Winston Chung, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LOS ALAMITOS, CA · NPI 1851322085
Verified facts
What the public records show
CMS Open Payments records show Winston Chung, MD received $281.71 in general payments during 2025 across 15 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lokelma by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 310 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $49.18 | 17.5% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $45.01 | 16.0% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.43 | 11.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $29.66 | 10.5% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $27.82 | 9.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.37 | 8.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.23 | 7.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.05 | 6.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.67 | 6.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.29 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $281.71 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $49.18 | 2 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $45.01 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.43 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $29.66 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 310 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
310 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 679 | 183 |
| Amlodipine Besylate | Amlodipine Besylate | 644 | 158 |
| Levothyroxine Sodium | Levothyroxine Sodium | 451 | 97 |
| Losartan Potassium | Losartan Potassium | 393 | 110 |
| Eliquis | Apixaban | 310 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 280 | 69 |
| Lisinopril | Lisinopril | 273 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 260 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 256 | 65 |
| Gabapentin | Gabapentin | 229 | 56 |
| Metformin Hcl | Metformin Hcl | 206 | 62 |
| Simvastatin | Simvastatin | 169 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 158 | 44 |
| Omeprazole | Omeprazole | 144 | 39 |
| Famotidine | Famotidine | 142 | 26 |
| Carvedilol | Carvedilol | 129 | 31 |
| Allopurinol | Allopurinol | 122 | 29 |
| Alendronate Sodium | Alendronate Sodium | 114 | 25 |
| Furosemide | Furosemide | 109 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 27 |
| Lorazepam | Lorazepam | 101 | 23 |
| Potassium Chloride | Potassium Chloride | 98 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 89 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 23 |
| Donepezil Hcl | Donepezil Hcl | 82 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 26 |
| Finasteride | Finasteride | 81 | 19 |
| Spironolactone | Spironolactone | 81 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 25 |
| Tramadol Hcl | Tramadol Hcl | 71 | 15 |
| Synthroid | Levothyroxine Sodium | 69 | 17 |
| Januvia | Sitagliptin Phosphate | 68 | 19 |
| Sertraline Hcl | Sertraline Hcl | 67 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 18 |
| Trazodone Hcl | Trazodone Hcl | 63 | 14 |
| Valsartan | Valsartan | 61 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 16 |
| Lovastatin | Lovastatin | 57 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 55 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | suppressed |
| Levetiracetam | Levetiracetam | 52 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 49 | 13 |
| Clonidine Hcl | Clonidine Hcl | 47 | suppressed |
| Ezetimibe | Ezetimibe | 47 | 17 |
| Azelastine Hcl | Azelastine Hcl | 45 | 15 |
| Montelukast Sodium | Montelukast Sodium | 45 | 13 |
| Mirtazapine | Mirtazapine | 43 | suppressed |
| Nifedipine Er | Nifedipine | 43 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | 15 |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Jardiance | Empagliflozin | 39 | 12 |
| Risedronate Sodium | Risedronate Sodium | 39 | 15 |
| Alprazolam | Alprazolam | 35 | 12 |
| Metformin Hcl Er | Metformin Hcl | 35 | 13 |
| Ramipril | Ramipril | 35 | suppressed |
| Colchicine | Colchicine | 34 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 30 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Prednisone | Prednisone | 28 | 14 |
| Atenolol | Atenolol | 27 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 16 |
| Risperidone | Risperidone | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 22 |
| Celecoxib | Celecoxib | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Cefdinir | Cefdinir | 23 | 22 |
| Glipizide | Glipizide | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Minoxidil | Minoxidil | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | 11 |
| Naproxen | Naproxen | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Prolia | Denosumab | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 13 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $281.71 · 15 records | Bayer Healthcare Pharmaceuticals Inc. | CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, Kerendia, NURTEC ODT, REXULTI, SMARTVEST | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error